|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...5657585960616263646566...6768» |
- Decadron (dexamethasone) / Merck (MSD)
Trial completion: S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis (clinicaltrials.gov) - Jun 4, 2012
P2, N=93, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed
- ||||| thalidomide / Generic mfg., zoledronic acid / Generic mfg.
Enrollment change: Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma (clinicaltrials.gov) - Jun 3, 2012
P3, N=68, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed N=120 --> 68
- ||||||| thalidomide / Generic mfg., zoledronic acid / Generic mfg.
Trial completion: Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma (clinicaltrials.gov) - Jun 3, 2012
P3, N=68, Completed, Sponsor: Mayo Clinic
N=120 --> 68 Active, not recruiting --> Completed
- ||| Privigen (human immune globulin intravenous 10%) / CSL Behring
Preclinical, Trial initiation date: A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Jun 2, 2012
P4, N=150, Recruiting, Sponsor: CSL Behring
Active, not recruiting --> Completed Initiation date: Jul 2011 --> Nov 2011
- |||| bortezomib / Generic mfg.
Trial completion, P4 data: Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) (clinicaltrials.gov) - May 31, 2012
P4, N=1121, Completed, Sponsor: Janssen Korea, Ltd., Korea
Initiation date: Jul 2011 --> Nov 2011 Active, not recruiting --> Completed
- plerixafor / Generic mfg.
Biomarker, New P1 trial, Tumor microenvironment: Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation (clinicaltrials.gov) - May 31, 2012
P1, N=16, Recruiting, Sponsor: Tufts Medical Center
- |||||||||| blisibimod (A-623) / Anthera Pharma
New P2/3 trial: MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP (clinicaltrials.gov) - May 30, 2012
P2/3, N=60, Not yet recruiting, Sponsor: Anthera Pharmaceuticals
- Promacta (eltrombopag) / Novartis
New P2 trial: Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) (clinicaltrials.gov) - May 30, 2012
P2, N=26, Recruiting, Sponsor: Fondazione Progetto Ematologia
- |||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - May 28, 2012
P2, N=60, Completed, Sponsor: Hamilton Health Sciences Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Enrollment closed: Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant (clinicaltrials.gov) - May 24, 2012
P2, N=30, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Trial completion: HERO: Survey Evaluating the Psychosocial Effects of Living With Haemophilia (clinicaltrials.gov) - May 23, 2012
P=N/A, N=1236, Completed, Sponsor: Novo Nordisk
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- | NovoSeven (eptacog alfa) / Novo Nordisk
Trial completion, Observational data: Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors (clinicaltrials.gov) - May 21, 2012
P=N/A, N=35, Completed, Sponsor: Novo Nordisk
Enrolling by invitation --> Completed Enrolling by invitation --> Completed
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment change: Preservation of Ovarian Function After Hematopoietic Cell Transplant (clinicaltrials.gov) - May 21, 2012
P2, N=47, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Enrolling by invitation --> Completed N=38 --> 47
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed: Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen (clinicaltrials.gov) - May 21, 2012
P1/2, N=60, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=38 --> 47 Completed --> Active, not recruiting
- | Doptelet (avatrombopag) / SOBI
Trial completion: Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine. (clinicaltrials.gov) - May 17, 2012
P1, N=36, Completed, Sponsor: Eisai Inc.
Completed --> Active, not recruiting Recruiting --> Completed
- | NovoSeven (eptacog alfa) / Novo Nordisk
New P2 trial: Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever (clinicaltrials.gov) - May 16, 2012
P2, N=28, Completed, Sponsor: Novo Nordisk
- | NovoSeven (eptacog alfa) / Novo Nordisk
New P2 trial, Surgery: Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction (clinicaltrials.gov) - May 16, 2012
P2, N=48, Completed, Sponsor: Novo Nordisk
- ||| Promacta (eltrombopag) / Novartis
Enrollment closed: A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - May 16, 2012
P4, N=150, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Active, not recruiting
- || dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Enrollment closed: Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone (clinicaltrials.gov) - May 15, 2012
P=N/A, N=100, Active, not recruiting, Sponsor: iOMEDICO AG
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Combination therapy, IO biomarker: A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma (clinicaltrials.gov) - May 15, 2012
P2, N=107, Completed, Sponsor: Janssen-Cilag Pty Ltd
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Simulect (basiliximab) / Novartis
Enrollment closed: Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer (clinicaltrials.gov) - May 14, 2012
P2, N=17, Active, not recruiting, Sponsor: Indiana University School of Medicine
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial withdrawal: Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) (clinicaltrials.gov) - May 9, 2012
P1, N=0, Withdrawn, Sponsor: University of California, San Diego
Recruiting --> Active, not recruiting Recruiting --> Withdrawn
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) (clinicaltrials.gov) - May 9, 2012
P1, N=0, Withdrawn, Sponsor: University of California, San Diego
Recruiting --> Withdrawn N=10 --> 0
- Alhemo (concizumab) / Novo Nordisk
Trial completion: Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects (clinicaltrials.gov) - May 9, 2012
P1, N=8, Completed, Sponsor: Novo Nordisk
N=10 --> 0 Active, not recruiting --> Completed
- Enrollment change: The Use of rFVIIa in Trauma Patients: A Multi-Center Case Registry (clinicaltrials.gov) - May 8, 2012
P=N/A, N=380, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=1000 --> 380
- Trial completion: The Use of rFVIIa in Trauma Patients: A Multi-Center Case Registry (clinicaltrials.gov) - May 8, 2012
P=N/A, N=380, Completed, Sponsor: University of California, San Francisco
N=1000 --> 380 Not yet recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Trial withdrawal, Combination therapy: Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - May 8, 2012
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Completed Suspended --> Withdrawn
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Combination therapy: Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - May 8, 2012
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
Suspended --> Withdrawn N=44 --> 0
- Trial completion: A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone (clinicaltrials.gov) - May 8, 2012
P1/2, N=30, Completed, Sponsor: Peter MacCallum Cancer Centre, Australia
N=44 --> 0 Active, not recruiting --> Completed
- ||||| dexamethasone / Generic mfg., lenalidomide / Generic mfg.
New P2 trial: Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - May 6, 2012
P2, N=194, Completed, Sponsor: Celgene Corporation
- dabigatran etexilate / Generic mfg.
New P1 trial: An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients (clinicaltrials.gov) - May 1, 2012
P1, N=10, Completed, Sponsor: Capital District Health Authority, Canada
- | New P1 trial: Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers (clinicaltrials.gov) - Apr 30, 2012
P1, N=24, Recruiting, Sponsor: Entegrion, Inc.
- Clinical: Hereditary Haemorrhagic Telangiectasia Flight Safety Study (clinicaltrials.gov) - Apr 29, 2012
P=N/A, N=145, Completed, Sponsor: Imperial College London
- NovoSeven (eptacog alfa) / Novo Nordisk
Clinical: Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors (clinicaltrials.gov) - Apr 25, 2012
P=N/A, N=8, Completed, Sponsor: Novo Nordisk
- prednisone / Generic mfg., melphalan / Generic mfg., carfilzomib / Generic mfg.
Clinical: Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP) (clinicaltrials.gov) - Apr 25, 2012
P1/2, N=68, Recruiting, Sponsor: Nantes University Hospital
Active, not recruiting --> Completed N=32 --> 68
- bortezomib / Generic mfg.
Trial termination: Study of Velcade (clinicaltrials.gov) - Apr 24, 2012
P2, N=18, Terminated, Sponsor: University of Arkansas
N=32 --> 68 Completed --> Terminated; study terminated due to low accrual
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial initiation date: Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 24, 2012
P1, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; study terminated due to low accrual Initiation date: Nov 2011 --> Apr 2012
- bortezomib / Generic mfg.
Trial initiation date: Study of Velcade (clinicaltrials.gov) - Apr 24, 2012
P2, N=18, Terminated, Sponsor: University of Arkansas
Initiation date: Nov 2011 --> Apr 2012 Initiation date: Aug 2005 --> Apr 2006
- bortezomib / Generic mfg.
Enrollment change: Study of Velcade (clinicaltrials.gov) - Apr 24, 2012
P2, N=18, Terminated, Sponsor: University of Arkansas
Initiation date: Aug 2005 --> Apr 2006 N=30 --> 18
- ||| New P1 trial: Anfibatide Phase 1 Clinical Trial in Healthy Volunteers (clinicaltrials.gov) - Apr 24, 2012
P1, N=94, Completed, Sponsor: Lee's Pharmaceutical Limited
- Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Enrollment open, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Apr 23, 2012
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 18 Not yet recruiting --> Recruiting
- | Promacta (eltrombopag) / Novartis
Trial completion: PLATEFUN: Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag (clinicaltrials.gov) - Apr 18, 2012
P4, N=30, Completed, Sponsor: Ingrid Pabinger, MD
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Vonjo (pacritinib) / CTI BioPharma
Trial completion: A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis (clinicaltrials.gov) - Apr 18, 2012
P1/2, N=55, Completed, Sponsor: S*BIO
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
New P1 trial, Monotherapy: XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease (clinicaltrials.gov) - Apr 18, 2012
P1, N=22, Recruiting, Sponsor: Massachusetts General Hospital
- Promacta (eltrombopag) / Novartis
Enrollment open: Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Apr 18, 2012
P2, N=24, Recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial termination: Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant (clinicaltrials.gov) - Apr 17, 2012
P1, N=3, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Slow accrual.
- Enrollment change: Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant (clinicaltrials.gov) - Apr 17, 2012
P1, N=3, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Terminated; Slow accrual. N=32 --> 3
- |||| Zelboraf (vemurafenib) / Roche
Enrollment open: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers (clinicaltrials.gov) - Apr 17, 2012
P2, N=160, Recruiting, Sponsor: Hoffmann-La Roche
N=32 --> 3 Not yet recruiting --> Recruiting
- ||| dexamethasone / Generic mfg., pomalidomide / Generic mfg.
Clinical: CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis (clinicaltrials.gov) - Apr 17, 2012
P2, N=258, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
Trial completion: CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Apr 17, 2012
P2, N=89, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Terminated --> Completed